MedPath

TWO DOSES OF DEXMEDETOMIDINE AS AN ADJUVANT TO INTRATHECAL HYPERBARIC ROPIVACAINE.

Phase 4
Conditions
Health Condition 1: M810- Age-related osteoporosis without current pathological fractureHealth Condition 2: O- Medical and SurgicalHealth Condition 3: M171- Unilateral primary osteoarthritisof knee
Registration Number
CTRI/2023/05/052743
Lead Sponsor
CHANDINI MISHRA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.American society of Anaesthesiologist (ASA) Physical Status I and II posted for

elective lower limb surgeries.

2.Patients of age 18-60 years of either sex.

Exclusion Criteria

1.History of allergy to the drugs used in the study like ropivacaine,dexmedetomidine.

2.pregnant women

3.deformity in spine.

4.patients with sinus bradycardia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
â?¢. Postoperative VAS score. <br/ ><br>Timepoint: 2,4,6,8,12 hours <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1.The incidence of hypotension and bradycardia intraoperatively. <br/ ><br>2. Time taken for onset of sensory component by using the cold swab test till the <br/ ><br>loss of sensations.Timepoint: 2HRS,4HRS,6HRS,12HRS.
© Copyright 2025. All Rights Reserved by MedPath